Australia’s Pharmaceutical Benefits Scheme (PBS) expands subsidised access to Keytruda (pembrolizumab), enabling thousands more people with advanced cancer to receive the immunotherapy. The change is presented as a major expansion of eligibility for treatment under the national medicines subsidy scheme.
Both outlets report the update will extend coverage to additional patient groups, including people with ovarian cancer. They describe the move as increasing access to immunotherapy for patients who may otherwise face barriers due to cost. While the reports do not provide detailed clinical criteria in the excerpts, they broadly agree that the PBS listing expansion increases the number of Australians who can access Keytruda.
Across the coverage, the shared emphasis is on scale—thousands more patients gaining subsidised treatment—and on the eligibility expansion reaching cancers beyond the existing covered indications. The two sources align on the core development, focusing on the impact for patients through the PBS change.
